GHRS Stock Analysis: GH Research | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.844m USD | 12M Return: 79.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.28M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GH Research PLC (NASDAQ: GHRS) is a Dublin-based, clinical-stage biopharmaceutical company founded in 2018 that is developing novel therapies for depression and related psychiatric conditions. Its lead candidate, GH001, is an inhalable formulation of mebufotenin (5-MeO-DMT) currently in a Phase 2b trial for treatment-resistant depression, with earlier-stage Phase 2a studies in bipolar II disorder and postpartum depression. A second candidate, GH002, is an intravenous mebufotenin formulation being evaluated in a Phase 1 pharmacology study in healthy volunteers. As a clinical-stage biotech, the company is pre-revenue and focused on advancing its psychedelic-based pipeline through clinical milestones, which are the primary value drivers for investors in this segment of the healthcare sector.
- GH001 Phase 2b data readout in treatment-resistant depression
- FDA breakthrough therapy designation decision for GH001
- Cash runway and capital allocation through key clinical milestones
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA -4.01 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.17 > 3% & CFO -46.3m > Net Income -56.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 23.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.0m) vs 12m ago 6.90% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -159.5 > 6 (EBIT TTM -58.9m / Interest Expense TTM 369k) |
| A: 0.95 (Total Current Assets 272.2m - Total Current Liabilities 11.8m) / Total Assets 275.3m |
| B: -0.63 (Retained Earnings -173.2m / Total Assets 275.3m) |
| C: -0.20 (EBIT TTM -58.9m / Avg Total Assets 297.9m) |
| D: 22.15 (Book Value of Equity 263.4m / Total Liabilities 11.9m) |
| Altman-Z'' = 26.09 = AAA |
As of July 08, 2026, the stock is trading at USD 26.89 with a total of 151,141 shares traded. Over the past week, the price has changed by -5.62%, over one month by +33.65%, over three months by +83.17% and over the past year by +79.21%.
Current recommended Stop Loss: 22.40 (which is 16.7% or 2.7 ATR below the current price).
GH Research has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy GHRS.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 39.5 | 46.9% |
P/B = 7.0022
Revenue TTM = 0.0 USD
EBIT TTM = -58.9m USD
EBITDA TTM = -58.5m USD
Long Term Debt = 75.0k USD (estimated: total debt 432k - short term 357k)
Short Term Debt = 357k USD (from shortTermDebt, last quarter)
Debt = 432k USD (from shortLongTermDebtTotal, last quarter) (leases 432k already included)
Net Debt = -266.9m USD (calculated: Debt 432k - CCE 267.3m)
Enterprise Value = 1.58b USD (1.84b + Debt 432k - CCE 267.3m)
Interest Coverage Ratio = -159.5 (Ebit TTM -58.9m / Interest Expense TTM 369k)
EV/FCF = -33.91x (Enterprise Value 1.58b / FCF TTM -46.5m)
FCF Yield = -2.95% (FCF TTM -46.5m / Enterprise Value 1.58b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 350k) / Revenue TTM)
Tobins Q-Ratio = 5.73 (Enterprise Value 1.58b / Total Assets 275.3m)
Interest Expense / Debt = 85.42% (Interest Expense 369k / Debt 432k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -46.5m (EBIT -58.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 23.04 (Total Current Assets 272.2m / Total Current Liabilities 11.8m)
Debt / Equity = 0.00 (Debt 432k / totalStockholderEquity, last quarter 263.4m)
Debt / EBITDA = 4.56 (negative EBITDA) (Net Debt -266.9m / EBITDA -58.5m)
Debt / FCF = 5.74 (negative FCF - burning cash) (Net Debt -266.9m / FCF TTM -46.5m)
Total Stockholder Equity = 284.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.94% (Net Income -56.4m / Total Assets 275.3m)
RoE = -19.83% (Net Income TTM -56.4m / Total Stockholder Equity 284.4m)
RoCE = -20.69% (EBIT -58.9m / Capital Employed (Equity 284.4m + L.T.Debt 75.0k))
RoIC = -17.63% (negative operating profit) (NOPAT -46.5m / Invested Capital 263.8m)
WACC = 11.59% (E(1.84b)/V(1.84b) * Re(11.59%) + (debt cost/tax rate unavailable))
Discount Rate = 11.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.89 | Cagr: 8.13%
[DCF] Fair Price = unknown (Cash Flow -46.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.84 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.32 | Chg30d=-10.13% | Revisions=-44% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.36 | Chg30d=-6.26% | Revisions=-44% | Analysts=8
EPS current Year (2026-12-31): EPS=-1.40 | Chg30d=-5.91% | Revisions=-50% | GrowthEPS=-77.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.00 | Chg30d=-8.88% | Revisions=-50% | GrowthEPS=-42.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -62% (up=4, down=22)